Alaunos Therapeutics, Inc. (TCRT) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Alaunos Therapeutics, Inc. (TCRT) Reports In-Line Q2 EPS

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

August 15, 2022 7:00 AM EDT

Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with second dose levelExtended Cooperative Research and Development Agreement for development of personalized TCR-T cell therapies with the National Cancer Institute of the National Institute of Health to 2025Appointed Abhishek Srivastava, Ph.D. as VP, Technical OperationsAdvancing multi-pronged strategy to bolster in-house manufacturing capacityOperating cash burn in 2Q 2022 was $8.2 million, a decrease of 62% from the same period last year... More